Albert David Ltd
Incorporated in 1938, Albert David
Ltd is in the business of manufacturing pharmaceutical products[1]
- Market Cap ₹ 398 Cr.
- Current Price ₹ 697
- High / Low ₹ 944 / 580
- Stock P/E
- Book Value ₹ 686
- Dividend Yield 0.72 %
- ROCE 0.77 %
- ROE -0.38 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 1.02 times its book value
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 6.25% over past five years.
- Company has a low return on equity of 8.07% over last 3 years.
- Earnings include an other income of Rs.7.45 Cr.
- Working capital days have increased from 80.3 days to 247 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 317 | 318 | 293 | 285 | 316 | 320 | 246 | 313 | 341 | 362 | 345 | 334 | |
| 281 | 286 | 266 | 267 | 286 | 289 | 227 | 272 | 297 | 315 | 342 | 328 | |
| Operating Profit | 37 | 31 | 27 | 18 | 30 | 30 | 19 | 41 | 44 | 47 | 3 | 5 |
| OPM % | 12% | 10% | 9% | 6% | 10% | 10% | 8% | 13% | 13% | 13% | 1% | 2% |
| 2 | 43 | 8 | 9 | 15 | 7 | 17 | 16 | 15 | 58 | 30 | 7 | |
| Interest | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 3 |
| Depreciation | 15 | 9 | 8 | 8 | 7 | 8 | 8 | 9 | 9 | 7 | 7 | 10 |
| Profit before tax | 20 | 63 | 26 | 18 | 38 | 29 | 27 | 47 | 51 | 97 | 25 | 1 |
| Tax % | 32% | 24% | 39% | 45% | 29% | 34% | 19% | 25% | 29% | 22% | 32% | 379% |
| 14 | 48 | 16 | 10 | 27 | 19 | 22 | 35 | 36 | 75 | 17 | -1 | |
| EPS in Rs | 24.00 | 84.10 | 27.96 | 17.24 | 46.68 | 33.59 | 38.79 | 61.78 | 63.38 | 132.15 | 30.14 | -2.61 |
| Dividend Payout % | 23% | 7% | 20% | 32% | 13% | 21% | 15% | 15% | 14% | 9% | 17% | -192% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 6% |
| 3 Years: | -1% |
| TTM: | -3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -109% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 5% |
| 3 Years: | 1% |
| 1 Year: | -24% |
| Return on Equity | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 10% |
| 3 Years: | 8% |
| Last Year: | 0% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Reserves | 87 | 131 | 177 | 180 | 205 | 217 | 239 | 274 | 306 | 377 | 387 | 386 |
| 30 | 20 | 30 | 28 | 0 | 2 | 2 | 6 | 5 | 3 | 12 | 30 | |
| 71 | 67 | 71 | 76 | 84 | 95 | 95 | 116 | 106 | 112 | 107 | 98 | |
| Total Liabilities | 193 | 224 | 285 | 290 | 295 | 320 | 341 | 401 | 423 | 498 | 511 | 519 |
| 49 | 44 | 87 | 83 | 77 | 91 | 84 | 88 | 80 | 83 | 99 | 100 | |
| CWIP | 5 | 5 | 9 | 5 | 5 | 2 | 1 | 1 | 3 | 7 | 2 | 21 |
| Investments | 16 | 48 | 59 | 68 | 113 | 122 | 138 | 183 | 193 | 273 | 260 | 243 |
| 122 | 127 | 130 | 134 | 99 | 106 | 119 | 130 | 148 | 135 | 151 | 155 | |
| Total Assets | 193 | 224 | 285 | 290 | 295 | 320 | 341 | 401 | 423 | 498 | 511 | 519 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 28 | 68 | 20 | 30 | 32 | 30 | 37 | 40 | 11 | 46 | -28 | -8 | |
| -9 | -38 | -36 | -11 | -19 | -20 | -37 | -40 | -5 | -33 | 23 | -4 | |
| -18 | -18 | 7 | -5 | -17 | -10 | -2 | -2 | -6 | -8 | 0 | 12 | |
| Net Cash Flow | 1 | 12 | -10 | 15 | -4 | 0 | -2 | -1 | -1 | 4 | -5 | -0 |
| Free Cash Flow | 18 | 62 | -0 | 31 | 45 | 15 | 35 | 32 | 6 | 35 | -43 | -36 |
| CFO/OP | 95% | 303% | 115% | 204% | 126% | 149% | 202% | 129% | 59% | 131% | -629% | -49% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 47 | 41 | 41 | 35 | 25 | 34 | 29 | 29 | 32 | 30 | 29 | 37 |
| Inventory Days | 176 | 187 | 217 | 173 | 151 | 148 | 151 | 124 | 149 | 126 | 201 | 187 |
| Days Payable | 103 | 102 | 117 | 127 | 102 | 132 | 104 | 96 | 95 | 98 | 118 | 104 |
| Cash Conversion Cycle | 120 | 126 | 141 | 81 | 74 | 50 | 76 | 57 | 87 | 58 | 112 | 120 |
| Working Capital Days | 27 | 25 | 24 | 10 | 21 | 18 | -10 | -34 | 14 | -13 | 6 | 247 |
| ROCE % | 18% | 17% | 15% | 7% | 18% | 14% | 12% | 17% | 17% | 28% | 6% | 1% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Large Volume Parenteral (LVP) share of total revenue % |
|
||||||||||
| Manufactured goods share of total revenue % |
|||||||||||
| Domestic (India) sales share of total revenue % |
|||||||||||
| Permanent employees on rolls count |
|||||||||||
| R&D expenditure as % of total turnover % |
|||||||||||
| Number of stockists (CFA) pan-India count |
|||||||||||
| Placentrex (flagship brand) share of revenue % |
|||||||||||
| Top 5 customers share of net sales % |
|||||||||||
| R&D Expenditure (Percentage of Turnover) % |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
8h - Newspaper Publication dated 14.07.2026 regarding 87th AGM Notice dispatch along with Annual Report F.Y. 2025-26 to shareholders electronically and also via web-link letter to shareholders …
-
Reg. 34 (1) Annual Report.
1d - 87th AGM on 6 Aug 2026; record date 30 Jul, e-voting 3-5 Aug.
-
87Th AGM Has Been Scheduled On 6Th August, 2026 At 9:30 A.M.
1d - 87th AGM on 6 Aug 2026 via VC; e-voting 3-5 Aug, record date 30 Jul.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 4 Jul
-
Announcement under Regulation 30 (LODR)-Change in Management
4 Jul - Cluster-Head Saikath Banerjee resigned effective July 4, 2026, due to personal reasons.
Annual reports
-
Financial Year 2026
from bse
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
Business Overview:[1]
ADL is a part of the Kolkata-based Kothari Group. It is a prominent drug house, which is in the field of manufacturing Pharmaceutical Formulations, Infusion Solutions, Herbal Dosage Forms, Bulk Drugs, etc. Company is in strategic liaison with academic institutes like the Indian Institute of Chemical Biology (CSIR) & Department of Biotechnology, Calcutta University for outsourcing research.